ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy
Authors
Keywords
-
Journal
NEOPLASIA
Volume 22, Issue 12, Pages 725-744
Publisher
Elsevier BV
Online
2020-10-24
DOI
10.1016/j.neo.2020.09.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma
- (2020) Maximilian Pruss et al. BRITISH JOURNAL OF CANCER
- Imipridone Anticancer Compounds Ectopically Activate the ClpP Protease and Represent a New Scaffold for Antibiotic Development
- (2020) Samuel Jacques et al. GENETICS
- Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma
- (2020) Kyle Wierzbicki et al. Current Oncology Reports
- Targeting apoptosis in cancer therapy
- (2020) Benedito A. Carneiro et al. Nature Reviews Clinical Oncology
- Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype
- (2020) Wen Hu et al. Cancers
- Activation of dopamine receptor 2 (DRD2) prompts transcriptomic and metabolic plasticity in glioblastoma
- (2019) Seamus P. Caragher et al. JOURNAL OF NEUROSCIENCE
- EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma
- (2019) Jens-Martin Hübner et al. NEURO-ONCOLOGY
- Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues
- (2019) Paul R. Graves et al. ACS Chemical Biology
- Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality
- (2019) Jo Ishizawa et al. CANCER CELL
- ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma.
- (2019) Sharon L. Gardner et al. JOURNAL OF CLINICAL ONCOLOGY
- First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M–mutant pediatric diffuse intrinsic pontine glioma: a case report
- (2019) Matthew D. Hall et al. Journal of Neurosurgery-Pediatrics
- Cancer and the dopamine D2 receptor: a pharmacological perspective
- (2019) Jillian S Weissenrieder et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia
- (2019) Takenobu Nii et al. LEUKEMIA
- Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
- (2019) Mark N. Stein et al. Journal for ImmunoTherapy of Cancer
- PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism
- (2019) Siddhant U. Jain et al. Nature Communications
- Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201
- (2019) Andrew S. Chi et al. JOURNAL OF NEURO-ONCOLOGY
- EXTH-71. IND-ENABLING CHARACTERIZATION OF ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR NEURO-ONCOLOGY
- (2019) Varun Prabhu et al. NEURO-ONCOLOGY
- A Bayesian machine learning approach for drug target identification using diverse data types
- (2019) Neel S. Madhukar et al. Nature Communications
- Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
- (2019) Nölting et al. Cancers
- Biological activity of weekly ONC201 in adult recurrent glioblastoma patients
- (2019) Isabel Arrillaga-Romany et al. NEURO-ONCOLOGY
- Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment
- (2018) Jorge E. Romaguera et al. BRITISH JOURNAL OF HAEMATOLOGY
- H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis
- (2018) Bette K. Kleinschmidt-DeMasters et al. CLINICAL NEUROPATHOLOGY
- Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
- (2018) Jessica Wagner et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries
- (2018) Lindsey M. Hoffman et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms
- (2018) Jessica Wagner et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer
- (2018) Avital Lev et al. MOLECULAR CANCER RESEARCH
- ONC201 kills breast cancer cells in vitro by targeting mitochondria
- (2018) Yoshimi Endo Greer et al. Oncotarget
- Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor
- (2018) Andrea A. Hayes-Jordan et al. NEOPLASIA
- Role of Dopamine Receptors in the Anticancer Activity of ONC201
- (2018) Christina Leah B. Kline et al. NEOPLASIA
- Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
- (2018) Varun Vijay Prabhu et al. CLINICAL CANCER RESEARCH
- Imipridone (ONC201) and Radiation Therapy Combination Shows Promise in Breast Cancer Treatment
- (2018) S.R. Jhawar et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS
- (2018) Rohinton Tarapore et al. NEURO-ONCOLOGY
- Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5
- (2018) Mattias Carlsten et al. OncoImmunology
- ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms
- (2017) Marie D. Ralff et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
- (2017) Andrea Piunti et al. NATURE MEDICINE
- Trends in GPCR drug discovery: new agents, targets and indications
- (2017) Alexander S. Hauser et al. NATURE REVIEWS DRUG DISCOVERY
- EXTH-42. H3 K27M MUTANT GLIOMAS ARE SELECTIVELY KILLED BY ONC201, A SMALL MOLECULE INHIBITOR OF DOPAMINE RECEPTOR D2
- (2017) Andrew S Chi et al. NEURO-ONCOLOGY
- Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location
- (2017) Michael Karremann et al. NEURO-ONCOLOGY
- Identification of DNA-PKcs as a primary resistance factor of TIC10 in hepatocellular carcinoma cells
- (2017) Long Cheng et al. Oncotarget
- ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways
- (2017) Xiao Ni et al. Oncotarget
- Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
- (2017) Avital Lev et al. Oncotarget
- ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells
- (2017) Xun Yuan et al. Oncotarget
- A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma
- (2017) Isabel Arrillaga-Romany et al. Oncotarget
- The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma
- (2017) Yong-sheng Tu et al. NEOPLASIA
- Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors
- (2017) Varun V. Prabhu et al. PLoS One
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- mTOR inhibition sensitizes ONC201-induced anti-colorectal cancer cell activity
- (2016) Zhe-zhu Jin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent
- (2016) Qiangbo Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway
- (2016) Davide Bommarito et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy
- (2016) Junjian Wang et al. CELL DEATH AND DIFFERENTIATION
- CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1
- (2016) Y. Lee et al. CLINICAL CANCER RESEARCH
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Discovery and clinical introduction of first-in-class imipridone ONC201
- (2016) Joshua E. Allen et al. Oncotarget
- Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia
- (2016) Jonathan Bond et al. Oncotarget
- Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics
- (2016) Paloma Navarro et al. Cell Reports
- ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases
- (2016) C. Leah B. Kline et al. Science Signaling
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
- (2016) Jo Ishizawa et al. Science Signaling
- Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
- (2016) Djoke Hendriks et al. OncoImmunology
- Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
- (2016) Marcel A. Deken et al. OncoImmunology
- Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
- (2016) Robert J. Cardnell et al. PLoS One
- Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study
- (2016) Yuan Feng et al. PLoS One
- Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
- (2015) Alicia Cole et al. CANCER CELL
- Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10
- (2015) J. E. Allen et al. CANCER RESEARCH
- Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner
- (2015) V. V. Prabhu et al. CANCER RESEARCH
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells
- (2015) Mala K Talekar et al. CELL CYCLE
- The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults
- (2015) Jie Feng et al. HUMAN PATHOLOGY
- Genetic and Functional Analysis of Polymorphisms in the Human Dopamine Receptor and Transporter Genes in Small Cell Lung Cancer
- (2015) Emanuela Cherubini et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway
- (2015) Joshua E Allen et al. Molecular Cancer
- First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent
- (2015) Joshua E. Allen et al. PLoS One
- Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data
- (2015) H-W Cheng et al. Cell Death & Disease
- Targeting G protein coupled receptor-related pathways as emerging molecular therapies
- (2015) Abdelaziz Ghanemi SAUDI PHARMACEUTICAL JOURNAL
- TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo
- (2015) Georg Karpel-Massler et al. Oncotarget
- Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma
- (2015) Jie Li et al. Oncotarget
- Dopamine signaling: target in glioblastoma
- (2015) Jiri Bartek et al. Oncotarget
- The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity
- (2015) Jessica Wagner et al. Oncotarget
- Dopamine receptors - IUPHAR Review 13
- (2014) Jean-Martin Beaulieu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
- (2014) X. Wei Meng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dopamine Inhibits the Effector Functions of Activated NK Cells via the Upregulation of the D5 Receptor
- (2014) Joanna Mikulak et al. JOURNAL OF IMMUNOLOGY
- PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma
- (2014) Georg Karpel-Massler et al. PLoS One
- PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy
- (2013) K. Yuan et al. CLINICAL CANCER RESEARCH
- Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells
- (2013) Michael A. Sheard et al. JOURNAL OF IMMUNOTHERAPY
- Dopamine Receptors Modulate Cytotoxicity of Natural Killer Cells via cAMP-PKA-CREB Signaling Pathway
- (2013) Wei Zhao et al. PLoS One
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
- (2012) Dong-Anh Khuong-Quang et al. ACTA NEUROPATHOLOGICA
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells
- (2012) Eleftherios Sachlos et al. CELL
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
- (2012) Jeremy Schwartzentruber et al. NATURE
- Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
- (2012) Gang Wu et al. NATURE GENETICS
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
- (2012) Ashish Juvekar et al. Cancer Discovery
- Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors
- (2011) P. Neri et al. BLOOD
- Parkinson’s disease and cancer risk: a systematic review and meta-analysis
- (2010) Archna Bajaj et al. CANCER CAUSES & CONTROL
- PAR1 and PAR2 Couple to Overlapping and Distinct Sets of G Proteins and Linked Signaling Pathways to Differentially Regulate Cell Physiology
- (2010) K. L. McCoy et al. MOLECULAR PHARMACOLOGY
- G protein-coupled receptors: novel targets for drug discovery in cancer
- (2010) Rosamaria Lappano et al. NATURE REVIEWS DRUG DISCOVERY
- Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition
- (2009) E. Ames et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- G2A Deficiency in Mice Promotes Macrophage Activation and Atherosclerosis
- (2008) David T. Bolick et al. CIRCULATION RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started